$3.5M
1 filing since 2025 · latest Options filed
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for central nervous system disorders, with a particular focus on suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The company seeks to fulfill significant unmet medical needs within these areas by delivering novel treatment options that promise enhanced efficacy and safety.
What sets it apart
NRx Pharmaceuticals stands out with its breakthrough approach to treating severe psychiatric conditions through the modulation of the NMDA receptor, which offers a distinct mechanism of action compared to traditional therapies.
NRX-101 is an oral, fixed-dose combination therapy that incorporates D-cycloserine and lurasidone. It is specifically being developed for the treatment of suicidal bipolar depression and has received the esteemed FDA Breakthrough Therapy designation, which indicates its potential to offer significant improvements over existing treatment options.
